On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know

J Gen Intern Med. 2020 Apr;35(4):1285-1288. doi: 10.1007/s11606-020-05651-2. Epub 2020 Jan 21.

Abstract

Based on the results of the IPERGAY study, on-demand HIV pre-exposure prophylaxis (PrEP; also known as "non-daily PrEP," "event-driven PrEP," or "2-1-1 PrEP") is being requested more frequently by patients who have intermittent sexual risk or are unable/unwilling to take daily PrEP; therefore, clinicians will be increasingly required to familiarize themselves with its appropriate use. In this perspective, we summarize data related to on-demand PrEP, describe advantages and disadvantages for this alternative dosing strategy, and provide clinical counseling points.

Keywords: 2-1-1; PrEP; clinician; on-demand; pre-exposure prophylaxis; tenofovir/emtricitabine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Emtricitabine
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Humans
  • Pre-Exposure Prophylaxis*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Tenofovir
  • Emtricitabine